Copyright
©2007 Baishideng Publishing Group Co.
World J Gastroenterol. Aug 14, 2007; 13(30): 4085-4090
Published online Aug 14, 2007. doi: 10.3748/wjg.v13.i30.4085
Published online Aug 14, 2007. doi: 10.3748/wjg.v13.i30.4085
Table 3 HBV genotypes, variants, and lamivudine-resistant mutants
Patients with VBT | During BT | ||||||||||
Patient | Sex | BT | Genotype | Month after LAM | ALT | HBeAg | HBV DNA log10 copies/mL | PC | CP A1763T G1765A | L180M | M204I/V |
1 | F | + | C | 19 | 90 | - | 5.4 | Wild | TA | M | I/V |
2 | M | + | C | 18 | 29 | - | 3 | Stop | TA | L | I/V |
3 | F | + | C | 12 | 12 | + | 6.8 | Wild | AG | L | M |
4 | M | + | C | 18 | 44 | + | 8.3 | Wild | TA | M | I/V |
5 | M | + | C | 36 | NA | + | 5.2 | Wild | TA | M | I/V |
6 | F | + | C | 21 | 42 | + | 5.7 | Wild | AG | L | M |
7 | M | + | C | 27 | 24 | + | 6.6 | Stop | TA | M | I/V |
8 | F | + | C | 21 | NA | + | 6.7 | Wild | AG | L | M |
9 | F | + | C | 30 | 108 | + | 6.7 | Wild | TA | M | I/V |
Patients without VBT | End of follow-up | ||||||||||
Patient | Sex | BT | Genotype | Month after LAM | ALT | HBeAg | HBV DNA log10 copies/mL | PC | CP A1763T G1765A | L180M | M204I/V |
1 | M | - | C | 9 | 28 | + | 4.6 | Wild | TA | L | M |
2 | M | - | C | 30 | NA | + | 5.4 | Wild | TA | L | M |
3 | M | - | C | 32 | 12 | - | 1 | UD | UD | L | M |
4 | M | - | C | 27 | NA | + | 1 | Wild | TA | L | M |
5 | M | - | C | 36 | 42 | - | 1 | UD | UD | L | M |
6 | M | - | C | 24 | 24 | + | 1 | Wild | TA | UD | UD |
- Citation: Chae HB, Hann HW. Baseline HBV DNA level is the most important factor associated with virologic breakthrough in chronic hepatitis B treated with lamivudine. World J Gastroenterol 2007; 13(30): 4085-4090
- URL: https://www.wjgnet.com/1007-9327/full/v13/i30/4085.htm
- DOI: https://dx.doi.org/10.3748/wjg.v13.i30.4085